3/18
08:45 am
ganx
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 [Yahoo! Finance]
High
Report
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 [Yahoo! Finance]
3/18
08:15 am
ganx
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
High
Report
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
3/12
07:45 am
ganx
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update [Yahoo! Finance]
Low
Report
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update [Yahoo! Finance]
3/12
07:00 am
ganx
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Low
Report
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
2/19
07:34 am
ganx
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/19
07:00 am
ganx
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
1/7
07:00 am
ganx
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Medium
Report
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
1/6
07:00 am
ganx
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
High
Report
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
12/19
03:03 pm
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at Roth Capital.
12/19
08:04 am
ganx
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
12/18
04:05 pm
ganx
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
High
Report
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease